Targeting OX40 and OX40L for the treatment of autoimmunity and cancer
- PMID: 18197805
- DOI: 10.1615/critrevimmunol.v27.i5.20
Targeting OX40 and OX40L for the treatment of autoimmunity and cancer
Abstract
The optimal activation of naïve T cells requires TCR-mediated recognition of cognate peptide-MHC complexes on antigen presenting cells in the presence of costimulatory signals. Although signals provided via CD28-B7 interactions are important for enhancing the initial T-cell response, other costimulatory signals are required for sustaining the response and promoting both T-cell differentiation and survival. In particular, engagement of OX40 (CD134) by its natural ligand OX40L (CD134L) or OX40 agonists has been shown to provide key signals that can augment CD4 and CD8 T-cell responses. Importantly, numerous studies have highlighted the ability of OX40-specific agonists or antagonists to enhance antitumor immunity or ameliorate autoimmune disease, respectively. On the basis of these studies, the development of OX40- and OX40L-specific reagents has been pursued for clinical use. Given the emerging role of OX40 and OX40L as novel therapeutic targets, this review will focus on the cellular and molecular mechanisms of OX40-mediated T-cell costimulation with a special emphasis on the role of OX40-OX40L interactions in the etiology and treatment of autoimmunity and cancer.
Similar articles
-
OX40, OX40L and Autoimmunity: a Comprehensive Review.Clin Rev Allergy Immunol. 2016 Jun;50(3):312-32. doi: 10.1007/s12016-015-8498-3. Clin Rev Allergy Immunol. 2016. PMID: 26215166 Review.
-
OX40/OX40L axis: not a friend in autoimmunity.Oncotarget. 2015 Sep 8;6(26):21779-80. doi: 10.18632/oncotarget.4973. Oncotarget. 2015. PMID: 26314852 Free PMC article. No abstract available.
-
OX40 (CD134) and OX40L.Adv Exp Med Biol. 2009;647:94-107. doi: 10.1007/978-0-387-89520-8_6. Adv Exp Med Biol. 2009. PMID: 19760068 Review.
-
OX40L/OX40 axis impairs follicular and natural Treg function in human SLE.JCI Insight. 2018 Dec 20;3(24):e122167. doi: 10.1172/jci.insight.122167. JCI Insight. 2018. PMID: 30568041 Free PMC article.
-
Requirements for the functional expression of OX40 ligand on human activated CD4+ and CD8+ T cells.Hum Immunol. 2007 Jul;68(7):563-71. doi: 10.1016/j.humimm.2007.03.012. Epub 2007 Apr 13. Hum Immunol. 2007. PMID: 17584577
Cited by
-
Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer.Oncotarget. 2017 Aug 5;8(53):90825-90841. doi: 10.18632/oncotarget.19967. eCollection 2017 Oct 31. Oncotarget. 2017. PMID: 29207606 Free PMC article.
-
Mapping the landscape: a bibliometric study of global chimeric antigen receptor T cell immunotherapy research.Naunyn Schmiedebergs Arch Pharmacol. 2024 Dec;397(12):9227-9241. doi: 10.1007/s00210-024-03258-6. Epub 2024 Jul 2. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38953967 Review.
-
Challenges and opportunities in the development of combination immunotherapy with OX40 agonists.Expert Opin Biol Ther. 2023 Jul-Dec;23(9):901-912. doi: 10.1080/14712598.2023.2249396. Epub 2023 Aug 20. Expert Opin Biol Ther. 2023. PMID: 37587644 Free PMC article. Review.
-
Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity.Oncoimmunology. 2021 Mar 1;10(1):1892265. doi: 10.1080/2162402X.2021.1892265. Oncoimmunology. 2021. PMID: 33717655 Free PMC article.
-
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.Front Oncol. 2015 Feb 16;5:34. doi: 10.3389/fonc.2015.00034. eCollection 2015. Front Oncol. 2015. PMID: 25763356 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials